Cited by 303Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology

Open access
Lee, Seung-Hye, Meilandt, William J., Xie, Luke, Gandham, Vineela D., Ngu, Hai, Barck, Kai H., Rezzonico, Mitchell G., Imperio, Jose +10 more·2021·Neuron

Abstract

Loss-of-function TREM2 mutations strongly increase Alzheimer's disease (AD) risk. Trem2 deletion has revealed protective Trem2 functions in preclinical models of β-amyloidosis, a prominent feature of pre-diagnosis AD stages. How TREM2 influences later AD stages characterized by tau-mediated neurodegeneration is unclear. To understand Trem2 function in the context of both β-amyloid and tau pathologies, we examined Trem2 deficiency in the pR5-183 mouse model expressing mutant tau alone or in TauPS2APP mice, in which β-amyloid pathology exacerbates tau pathology and neurodegeneration. Single-cell RNA sequencing in these models revealed robust disease-associated microglia (DAM) activation in TauPS2APP mice that was amyloid-dependent and Trem2-dependent. In the presence of β-amyloid pathology, Trem2 deletion further exacerbated tau accumulation and spreading and promoted brain atrophy. Without β-amyloid pathology, Trem2 deletion did not affect these processes. Therefore, TREM2 may slow AD progression and reduce tau-driven neurodegeneration by restricting the degree to which β-amyloid facilitates the spreading of pathogenic tau.

Integrity signals

Registry

Crossref · 10.1016/j.neuron.2021.02.010

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TREM2 deletion exacerbates tau pathology and promotes brain atrophy in a mouse model overexpressing human tau with P301L and human APP.

    “In a recently published study, TREM2 deletion was found to exacerbate tau pathology and promote brain atrophy in a mouse model that overexpressed human tau with the P301L mutation and human amyloid precursor protein (APP) but had no effect in a model that solely overexpressed mutant tau, suggesting that TREM2 function is neither protective nor detrimental in a pure tauopathy setting [14].”

    From TREM2-Deficient Microglia Attenuate Tau Spreading In Vivo (2023) · cites this paper as [14]

  • Collectively, studies yielded disparate results regarding the effect of TREM2 on tau pathology and whether the effect is amyloid dependent or independent.

    “Collectively, these studies yielded disparate results regarding the effect of TREM2 on tau pathology and whether the effect is amyloid dependent or independent.”

    From TREM2-Deficient Microglia Attenuate Tau Spreading In Vivo (2023) · cites this paper as [14]

  • TREM2 deletion has no effect on tau pathology in a mouse model solely overexpressing mutant tau.

    “In a recently published study, TREM2 deletion was found to exacerbate tau pathology and promote brain atrophy in a mouse model that overexpressed human tau with the P301L mutation and human amyloid precursor protein (APP) but had no effect in a model that solely overexpressed mutant tau, suggesting that TREM2 function is neither protective nor detrimental in a pure tauopathy setting [14].”

    From TREM2-Deficient Microglia Attenuate Tau Spreading In Vivo (2023) · cites this paper as [14]

  • The dichotomy of immune effects on amyloid and tau has been demonstrated in multiple models of Trem2 and Tyrobp.

    “More recently, this dichotomy has been elegantly demonstrated in multiple models of Trem2 and Tyrobp [49–51, 55–59].”
  • Manipulation of Trem2, Tyrobp, Cx3cl1/Cx3cr1, IL1β, and IFN-γ have opposing effects on amyloid and tau pathologies.

    “Indeed, manipulation of expression of Trem2, Tyrobp, Cx3cl1/Cx3cr1, IL1β, and IFN-γ have all been shown to have opposing effects on amyloid and tau pathologies [49–51, 55–65].”

Cites

1 retracted

Flagged first, then by citations

1 of the 80 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Lee, S.-H., Meilandt, W. J., Xie, L., Gandham, V. D., Ngu, H., Barck, K. H., Rezzonico, M. G., Imperio, J., Lalehzadeh, G., Huntley, M. A., Stark, K. L., Foreman, O., Carano, R. A. D., Friedman, B. A., Sheng, M., Easton, A., Bohlen, C. J., & Hansen, D. V.
Affiliations
Genentech (US)
Corresponding author
  • Meilandt, William J.
  • Hansen, David V.
Venue
Neuron
Publisher
Elsevier BV
Published
2021-04
Volume
109
Issue
8
Pages
1283-1301.e6
ISSN
0896-6273 (ISSN-L)
OpenAlex
W3135733909
Cited by
300
References
80
Citations by year
2026: 32 · 2025: 51 · 2024: 56 · 2023: 45 · 2022: 82 · 2021: 33
FWCI
34.36
Type
journal article
Language
en
Open access
Locations
  • Neuron (publishedVersion)
  • PubMed (publishedVersion)
Funders
Genentech Inc
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
TREM2, Alzheimer's disease, amyloid-beta, tau pathology, neurodegeneration, disease-associated microglia, microglial activation, tau propagation, brain atrophy, TREM2 deficiency, disease progression
MeSH terms
Alzheimer Disease, Amyloid, Animals, Atrophy, Brain, Disease Models, Animal, Membrane Glycoproteins, Mice, Transgenic, Receptors, Immunologic, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, tau Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review